Search Results
Your search for The ASCO matches 21120 pages
Showing 14951 - 15000ASCO Updates Value in Cancer Care Framework
On May 31, 2016, ASCO published an updated framework for assessing the relative value of cancer therapies that have been compared in clinical trials. The framework, published by Schnipper et al,1 defines value as a combination of clinical benefit, side effects, and improvement in patient symptoms...
Yale Researchers Win Sokoloff Family-Melanoma Research Alliance Award
A new approach to understanding why T cells are often too weak to fight and destroy tumor cells has earned Yale Cancer Center researchers team science award from the Sokoloff Family-Melanoma Research Alliance. The $900,000 award will fund research over 3 years examining metabolic regulation of ...
Philip A. Salem, MD, Honored by President of Mexico for Cancer Care
Oncologist Philip A. Salem MD, Director Emeritus of Cancer Research at Baylor St. Luke’s Medical Center in Houston, was honored as a physician and author on April 28 by the President of Mexico Enrique Peña Nieto and his government for Dr. Salem’s lifelong commitment to cancer care worldwide. Dr....
AUA Honors Its 2016 Annual Award Winners
The American Urological Association (AUA) honored its 2016 AUA award recipients during its 111th Annual Meeting in San Diego, Calfornia. These physician researchers, educators, and organizations were honored for their contributions to the field of medicine, the specialty of urology, and the AUA....
Cheryl Taylore Lee, MD, Named Urology Chair at The Ohio State University Wexner Medical Center
The Ohio State University Wexner Medical Center has named a prominent expert in bladder cancer, Cheryl Taylore Lee, MD, to lead its urology, uro/gynecology, and uro/oncologic programs, beginning July 1, pending approval by The Ohio State University Board of Trustees. Dr. Lee will be Chair of the...
An Unusual Memoir of Cancer
“A book about the future must be written in advance. Later I won’t have the energy. So I will do it now.” So begins The Iceberg, a memoir set in Britain of a woman, Marion Coutts, whose husband was diagnosed with a brain tumor, which eventually killed him. Unfortunately, cancer memoirs flood the...
University of Maryland Greenebaum Cancer Center Designated as NCI Comprehensive Cancer Center
The University of Maryland Marlene and Stewart Greenebaum Cancer Center has been awarded the National Cancer Institute’s (NCI’s) highest designation as a Comprehensive Cancer Center. The prestigious distinction recognizes the cancer center’s high caliber of scientific leadership and robust programs ...
Dana-Farber President to Receive SPARK! Award for Health Promotion
The Albert Schweitzer Fellowship (ASF) announced its selections for the 2016 SPARK! Awards. Edward J. Benz, Jr, MD, President and CEO of Dana-Farber Cancer Institute, will receive the 2016 Schweitzer Clarion Award for Health Promotion and Education. Dr. Benz is being honored for bringing...
HOPA Research Grants Announced, Totaling Nearly $60,000 in Funding
The Hematology/Oncology Pharmacy Association (HOPA) has awarded two HOPA Research Grant Awards to Val Adams, PharmD, BCOP, FCCP, and Jill S. Bates, PharmD, MS, BCOP, for their respective research projects. The goal of HOPA’s Research Grant efforts are to fund work that results in facilitating...
Low-Dose Chemical Exposure and Cancer
According to estimates from the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC), environmental toxic exposures are responsible for between 7% and 19% of human cancers. However, the 2008–2009 President’s Cancer Panel Annual Report estimated that the “true...
FDA Approves New Diagnostic Imaging Agent to Detect Recurrent Prostate Cancer
On May 27, the U.S. Food and Drug Administration (FDA) approved fluciclovine F-18 (Axumin), a radioactive diagnostic agent for injection. Fluciclovine F-18 is indicated for positron-emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated...
Clinical Trials Actively Recruiting Patients With Liver Cancer
Pilot Study Title: Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma Study Type: Interventional/nonrandomized/parallel assignment Study Sponsor and Collaborators: Washington University School of Medicine Purpose: ...
Multi-Institutional Metastatic Melanoma Research Team Receives $900,000 L’Oréal Paris USA–MRA Team Science Award for Women in Scientific Research
An international, multi-institutional research team consisting of the Spanish National Cancer Research Centre (CNIO); The Wistar Institute; Cancer Research UK Edinburgh Centre; the Perelman School of Medicine at the University of Pennsylvania; and the Icahn School of Medicine at Mount Sinai has...
SIRIUS Trial Heralds a New Era of Promise in Treating Resistant Myeloma
Multiple myeloma cells uniformly overexpress CD38.1 Daratumumab (Darzalex), a CD38-targeting human IgG1 kappa monoclonal antibody, has been evaluated in a series of phase I/II trials involving patients with relapsed or relapsed and refractory myeloma who have received at least two or more prior...
American Cancer Society Report Assesses Progress Against Goals Set for Nation 25 Years Ago
A new report assesses how the nation fared against the ambitious goal set by the American Cancer Society (ACS) to reduce cancer death rates by 50% over 25 years ending in 2015. The report finds areas where progress was substantial, and others where it was not. Published by Byers et al,1 the report ...
ASCO 2016: CancerLinQ Extends Its Reach, Announces New Partnerships
ASCO announced that a total of 58 practices in 39 states and the District of Columbia have joined CancerLinQ™, ASCO’s big data initiative to rapidly improve the quality of care for people with cancer. CancerLinQ is already up and running in a number of practices and drawing on approximately...
Prostate Cancer: Opinions Vary on Gleason Scores and Surgery
Diagnosis and treatment of prostate cancer have been the source of heated debate for decades, most of which has centered on the clinical value of the prostate-specific antigen (PSA) test. In 2012, the U.S Preventive Services Task Force (USPSTF) gave the PSA test a D grade, which discourages many...
Newly Updated: Resources to Help Your Patients Quit Tobacco
Most smokers and other tobacco users want to quit. ASCO’s patient booklet Stopping Tobacco Use After a Cancer Diagnosis offers people with cancer and their caregivers information on tobacco cessation. With information on treatments and resources available, this booklet gives patients the practical...
2016 ASCO Annual Meeting Planning Committees
The ASCO Annual Meeting highlights the latest research and treatment advances in oncology, with nearly 30,000 oncology professionals attending each year. ASCO wishes to acknowledge the volunteers on this year’s Cancer Education and Scientific Program Committees and thank them for their time and...
ASCO Submits Comments to ONC on Enhanced Oversight of the HIT Certification Program
On Monday, May 2, ASCO submitted comments to the Office of the National Coordinator (ONC) regarding the proposed Enhanced Oversight of the ONC Health Information Technology (HIT) Certification Program rule. The rule would increase ONC oversight of certified health IT, define a process for...
Toni K. Choueiri, MD, and Paul L. Nguyen, MD, on Prostate Cancer: Expert Perspectives on Four Studies
Toni K. Choueiri, MD, and Paul L. Nguyen, MD, both of the Dana-Farber Cancer Institute, discuss four key studies on high- and intermediate-risk prostate cancer, as well as localized disease (Abstracts 5001, 5003, 5023, and 5021).
Lung Cancer Alliance Supports Two Young Investigator Awards
The Conquer Cancer Foundation of ASCO (CCF) has received generous support from Lung Cancer Alliance to fund a 2016 and 2017 Young Investigator Award (YIA) in lung cancer. Lung Cancer Alliance has a more than 20-year history of working to save lives and advance research by empowering those living...
Peter H. Wiernik, MD, Receives 2016 Walter Reed Distinguished Achievement Award From UVA Medical
The University of Virgina (UVA) Medical Alumni Association has recognized Peter H. Wiernik, MD, as co-recipient of its 2016 Walter Reed Distinguished Achievement Award. Dr. Wiernik received the award along with Charles W. Cummings, MD, former Chair of the Department of Otolaryngology–Head and Neck ...
Stephen K. Burley, MD, DPhil, Named Co–Program Leader at Rutgers
Stephen K. Burley, MD, DPhil, has been named as Co–Program Leader of the Cancer Pharmacology Research Program at Rutgers Cancer Institute of New Jersey. This basic science program unites investigators with broad scientific expertise who share a strong interest in cancer pharmacology and preclinical ...
PALOMA-3 Trial in HER2-Negative Metastatic Breast Cancer: Challenge of Moving Beyond Estrogen Receptor Positivity
Hormone receptor–positive breast cancer represents the largest therapeutic subgroup of the disease. The development of endocrine therapies has shaped the treatment paradigm for both advanced- and early-stage disease for decades.1 Still, despite their significant impact, advanced breast cancer...
QOPI Certification Program Certifies First International Practice
ASCO recently announced that the Contemporary Oncology Team of Athens, Greece, as part of the new international pilot project, is the first international practice to receive Quality Oncology Practice Initiative (QOPI®) certification through the QOPI Certification Program, LLC (QCP). “Achieving...
Learning About Fertility Is Important to Young Patients With Cancer
It is more and more common for people to wait until their 30s or 40s to have children. Consequently, many young adults have not completed their desired childbearing when they are diagnosed with cancer. Cancer treatments can impair fertility directly (usually via gonadotoxicity from chemotherapy,...
Richard J. O’Reilly, MD, Named The Society of MSK’s Inaugural Prize Winner for Groundbreaking Contributions in Pediatric Oncology
The Society of Memorial Sloan Kettering Cancer Center (MSK) has announced that Richard J. O’Reilly, MD, has been named the inaugural recipient of The Society of Memorial Sloan Kettering Prize. Founded in 1946, The Society of MSK is a volunteer-led organization within MSK dedicated to promoting the ...
Patient Advocate Michael Kaplan to Lead Melanoma Research Alliance
The Melanoma Research Alliance (MRA), the world’s largest private funder of melanoma research, has named Michael Kaplan as its new leader. For the past 20 years, Mr. Kaplan has headed various nonprofits and patient advocacy groups, including his most recent position as President and CEO of...
AACR CEO Margaret Foti, PhD, MD (hc), Honored With Ovarcome Excellence Award
Margaret Foti, PhD, MD (hc), Chief Executive Officer (CEO) of the American Association for Cancer Research (AACR), has received the Ovarcome Excellence 2016 Award in recognition of her accomplishments in the field of cancer research, and her commitment to increasing public awareness about cancer...
Sagar Lonial, MD, and Andrew Zelenetz, MD, PhD, on MCL, DLBCL, CLL: How Much Rituximab Is Enough?
Sagar Lonial, MD, of Emory University School of Medicine, and Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss newly reported findings on rituximab maintenance therapy in hematologic malignancies (Abstracts 7503, 7504, and 7505).
Combined-Modality Therapy for Low-Grade Gliomas: Balancing Toxicity, Delivery Logistics, and Survival Benefit
Low-grade gliomas account for 15% of all primary brain tumors and represent a heterogeneous group of glial neoplasms. Although these tumors have been termed low-grade, this is a misnomer, especially for some grade II gliomas, which may exhibit a more aggressive behavior and variable natural...
Lisa A. Carey, MD, and Ann Partridge, MD, MPH, Appointed Co-Chairs of the Alliance for Clinical Trials in Oncology Breast Committee
Lisa A. Carey, MD, of the University of North Carolina (UNC), and Ann Partridge, MD, MPH, of Dana-Farber Cancer Institute, have been appointed Co-Chairs of the Alliance for Clinical Trials in Oncology Breast Committee. The Alliance for Clinical Trials in Oncology develops and conducts cancer...
Ovarian Suppression in Premenopausal Women With Estrogen Receptor–Positive Breast Cancer
Oophorectomy was the first proposed form of endocrine therapy for women with breast cancer. Over 100 years ago, Thomas Nunn reported a relationship between menopause and regression of breast cancer.1 This incited interest in the induction of menopause as an anticancer therapy, and in 1986, a...
ASCO Clinical Practice Guideline Update on Ovarian Suppression/Adjuvant Endocrine Therapy in Hormone Receptor–Positive Breast Cancer
As reported in the Journal of Clinical Oncology by Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, and colleagues, ASCO has released a clinical practice guideline update on ovarian suppression as part of the extant guideline on adjuvant endocrine therapy in hormone...
ASCO Applauds the FDA for Regulating E-Cigarettes
ASCO President Julie M. Vose, MD, MBA, FASCO, issued the following statement in response to the U.S. Food and Drug Administration’s (FDA) move to regulate electronic cigarettes. “ASCO applauds the FDA for exercising its congressionally mandated authority to regulate cigars, hookah tobacco,...
Statement From FDA Commissioner Robert Califf, MD, on the Release of the Final Individual Patient Expanded Access Form
On June 2, 2016, U.S. Food and Drug Administration (FDA) Commissioner Robert Califf, MD, issued the following statement on the release of the final individual patient expanded access form. “Today, the FDA finalized its efforts to streamline the process used by physicians to request expanded...
Dr. William Morton and His Engineer
A Century of Progress The text and photograph on this page are excerpted from a four-volume series of books titled Oncology Tumors & Treatment: A Photographic History, by Stanley B. Burns, MD, FACS. The photo below is from the volume titled “The Antiseptic Era: 1876–1900.” To view additional...
Seattle Children’s Reports Promising Early Results With Immunotherapy in Relapsed ALL
Seattle Children’s announced that 39 of 42 patients treated in a phase I clinical trial using genetically reprogrammed T cells to treat relapsed or refractory acute lymphoblastic leukemia (ALL) have achieved complete remission, showing no detectable leukemia cells. Phase II of this trial, known as...
Fabrice Denis, MD, PhD, on Lung Cancer: Improving OS With an App (French Language Version) 
Fabrice Denis, MD, PhD, of the Institut Inter-regional de Cancérologie Jean Bernard, discusses findings from a phase III trial on an app used between visits for early detection of symptomatic relapse and complications in high-risk lung cancer patients (Abstract LBA9006). To see the English...
Sagar Lonial, MD, and Paul G. Richardson, MD, on Multiple Myeloma: Expert Perspectives on Treatment Advances
Sagar Lonial, MD, of Emory University School of Medicine, and Paul G. Richardson, MD, of the Dana-Farber Cancer Institute, discuss the top presentations on multiple myeloma delivered at this year’s meeting.
Moving the Needle on HPV Vaccination
In 2012–2013, members of the President’s Cancer Panel (prescancerpanel.cancer.gov) focused their efforts on accelerating widespread acceptance of and use of approved human papillomavirus (HPV) vaccines to prevent cancer. The topic is important, because HPVs cause most cases of cervical cancer and...
Celestia S. Higano, MD, and Chris Parker, MD, on the PROMIS Study of Elevated PSA
Celestia S. Higano, MD, of the University of Washington, and Chris Parker, MD, of the Royal Marsden Hospital, discuss findings from this confirmatory study evaluating the accuracy of MRI and TRUS biopsy in men with an elevated PSA (Abstract 5000).
Lisa A. Carey, MD, and Nicholas C. Turner, MD, PhD, on PALOMA-2 and -3 Study Findings in Advanced Breast Cancer
Lisa A. Carey, MD, of the University of North Carolina, and Nicholas C. Turner, MD, PhD, of The Royal Marsden Hospital and Institute of Cancer Research, discuss the efficacy of palbociclib plus fulvestrant in patients with ESR1 mutations in circulating tumor DNA, and palbociclib and letrozole for...
University of Catania Presents Margaret Foti Scholar-in-Training Award to Saverio Candido, PhD
The American Association for Cancer Research (AACR) congratulates Saverio Candido, PhD, on receiving the fourth Margaret Foti Scholar-in-Training Award from the University of Catania in Italy. Dr. Candido is being recognized for his research on biomarkers of bladder cancer development and...
ASCO Statement on Human Papillomavirus Vaccination for Cancer Prevention
As reported in the Journal of Clinical Oncology by Howard H. Bailey, MD, of the University of Wisconsin Carbone Cancer Center, and colleagues, ASCO has released a statement on increasing human papillomavirus (HPV) vaccination to prevent HPV-related cancers in the United States.1 In the United...
It Started With Twitter: ASBrS Immediate Past-President, Deanna Attai, MD, Spearheads Patient-Centered Care
Breast surgeon Deanna Attai, MD, is a virtual mighty mouse as a spokesperson for her professional organization, the American Society of Breast Surgeons (ASBrS). She is as big on ideas as she is petite in stature and for actively tweeting on medical topics (@DrAttai). Assistant Clinical Professor...
Vice President Joe Biden Addresses Attendees at ASCO 2016 Annual Meeting
Vice President Joe Biden offered remarks on the White House’s National Cancer Moonshot Initiative on Monday, June 6, to attendees at the 2016 ASCO Annual Meeting in Chicago. Essential Elements “The Moonshot Initiative can be a vehicle for major new progress against cancer, and ASCO’s Annual...
Adjuvant Chemotherapy Improves Survival in Pancreatic Cancer
An adjuvant chemotherapy regimen improved overall survival in early-stage pancreatic cancer patients, in the large phase III European ESPAC-4 study reported at the 2016 ASCO Annual Meeting.1 The combination of gemcitabine and capecitabine almost doubled the 5-year survival rate, compared to...
Expert Point of View: Stuart A. Grossman, MD, and Deborah Schrag, MD
Formal discussant of this trial Stuart A. Grossman, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, commented that the trial did not include a best standard-of-care arm. The pivotal trial defined optimal radiotherapy as 60 Gy over 6 weeks, but this...
